Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. 1995

M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
Department of Internal Medicine and Geriatrics, University of Catania, Italy.

Patients with chronic active hepatitis C show low lipoprotein(a) (Lp[a]) values. We studied the changes in Lp(a) levels caused by treatment with interferon in 24 patients (9 men and 15 women; mean age, 56.8 +/- 7.3 years) affected by chronic active hepatitis C. Fifteen healthy subjects (6 men and 9 women; mean age, 57.4 +/- 10.3 years) were used as controls. All of the patients with chronic hepatitis C were treated with intramuscular interferon, 3 million units 3 times per week for 6 months. These patients had lower baseline serum Lp(a) concentrations than the controls (4.8 +/- 3.8 mg/dL vs 13.4 +/- 10.3 mg/dL, respectively; P = 0.0007). A significant increase in Lp(a) levels (6.6 +/- 7.2 mg/dL; P = 0.05) occurred after 6 months of treatment in patients with chronic active hepatitis C. Only complete responders presented a significant increase in Lp(a) values (P = 0.01). We believe that increased Lp(a) levels represent an expression of improved liver functions.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
October 1992, Acta medica Okayama,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
July 1997, Gut,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
May 1993, Gastroenterology,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
April 1997, Digestive diseases and sciences,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
January 2005, Clinical chemistry and laboratory medicine,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
July 1999, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
September 1997, International journal of clinical pharmacology and therapeutics,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
August 2003, Autoimmunity,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
January 1997, Thorax,
M Malaguarnera, and I Giugno, and B A Trovato, and M P Panebianco, and R Siciliano, and P Ruello
October 1995, Hepatology (Baltimore, Md.),
Copied contents to your clipboard!